Patents by Inventor David A. Cheresh

David A. Cheresh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240067733
    Abstract: Provided are compositions and methods for treating or ameliorating a cancer by targeting cell surface-expressed ?v?3 (avb3) polypeptides in Cancer Stem Cells (CSCs) to kill the CSCs, thus treating ameliorating or slowing the development of cancers caused or initiated by or sustained by cancer or tumor cells, or Cancer Stem Cells (CSCs), expressing ?v?3 polypeptides on their cell surfaces. Provided are compositions and methods for targeting and killing ?v?3-positive Cancer Stem Cells (CSCs) and treating drug resistant cancers. In alternative embodiments, compositions and methods as provided herein use an antibody that can specifically bind to human ?v?3 that also comprises an Fc portion that can mediate antibody-dependent un-mediated cytotoxicity (ADCC) killing of cancer or tumor cells by macrophages; for example, use a humanized antibody to ?v?3 that has been modified to include an engineered Fc portion that specifically binds to human macrophages.
    Type: Application
    Filed: October 4, 2023
    Publication date: February 29, 2024
    Inventors: David Cheresh, Hiromi Wettersten
  • Publication number: 20230417764
    Abstract: Provided are methods for determining whether a glioblastoma (GBM) tumor or GBM cancer cell will be sensitive to a treatment targeting the integrin avb3 (?v?3) pathway, comprising determining whether the GBM tumor or the GBM cancer cell expresses both avb3+ and Glut3+ along with a specific genetic signature associated with Glut3 addiction, where in alternative embodiments a cell is Glut3 addiction if the GBM tumor or the GBM cancer cell has markers consistent with the Classical or the Proneural molecular subtypes of GBM, or, expresses markers consistent with a Glut3-addicted molecular signature, e.g., as listed in FIG. 11 or FIG. 23. Also provided herein are methods of treating glioblastoma (GBM) tumors found to be sensitive to agents targeting or inhibiting the integrin avb3 (?v?3) pathway, wherein the sensitivity is determined by methods as provided herein.
    Type: Application
    Filed: May 9, 2023
    Publication date: December 28, 2023
    Inventors: David CHERESH, Sara Weis, Erika COSSET
  • Publication number: 20230140868
    Abstract: The present invention relates to chimeric binding agents and compositions comprising the same. The invention further relates to polynucleotides encoding the chimeric binding agent and vectors and host cells comprising the same. The invention further relates to methods of using the chimeric binding agents to mediate antibody-dependent cellular cytotoxicity of epithelial cancer cells and methods of treating epithelial cell cancers.
    Type: Application
    Filed: April 23, 2021
    Publication date: May 11, 2023
    Inventors: David Cheresh, Sara Weis, Stephen McCormack, Christoph Rader, Hiromi Wettersten
  • Patent number: 11052089
    Abstract: In alternative embodiments, provided are compositions and methods for treating, enhancing the drug sensitivity of, and preventing the formation of cancer stems cells, including preventing or slowing the development or generation of a beta-3 (?3)-expressing, or integrin ?3 (ITG-B3)-expressing cancer or tumor cells. In alternative embodiments, provided are methods using histone acetyl transferase inhibitors and/or histone methyl transferase inhibitors to determine therapeutic values in cancer cells that induce an integrin ?3 (ITGB3) polypeptide expression. In alternative embodiments, provided are kits, blister packages, lidded blisters or a blister card or packet, clamshells, trays or shrink wraps, comprising at least one compound, composition or formulation used to practice a method as provided herein, and at least one Growth Factor Inhibitor.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 6, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David A. Cheresh, Maricel Gozo, Mayra Yebra, Laetitia Seguin
  • Patent number: 11021755
    Abstract: In alternative embodiments, provided are products of manufacture, such as assays, chimeric nucleic acids and nucleic acid constructs, recombinant cells, and methods, comprising use of beta3-integrin (ITGB3) promoters operatively linked to a reporter, for drug screening, and in particular, screening for agents that inhibit cancer cell survival and metastasis. In alternative embodiments, compositions and methods as provided herein also can be used to identifying novel pathways that lead to acquired resistance, stemness, and anchorage independent growth; and characterizing distinct populations of cancer cells within a tumor microenvironment.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: June 1, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David Cheresh, Maricel Gozo, Mayra Yebra, Laetitia Seguin
  • Publication number: 20210032348
    Abstract: In alternative embodiments, provided are compositions and methods for treating or ameliorating an advanced cancer such as a drug resistant or metastatic cancer which express ?v?3 polypeptides on their cell surfaces, or for killing Cancer Stem Cells (CSCs) which express ?v?3 polypeptides on their cell surfaces, by using human or humanized antibodies capable of specifically binding cell surface-expressed ?v?3 (avb3) polypeptides whose Fc region has a selective affinity to human Fc?R1 (CD64), but not to other Fc?Rs, on effector cells such as macrophages, neutrophils, and dendritic cells. By administering these antibodies to an individual in need thereof, these human or humanized antibodies are capable of treating, ameliorating or slowing the development of the advanced cancer or drug resistant cancer, or a cancer caused or initiated by or sustained by an advanced cancer or drug resistant cancer cell, or a Cancer Stem Cell (CSC).
    Type: Application
    Filed: July 31, 2020
    Publication date: February 4, 2021
    Inventors: David CHERESH, Hiromi WETTERSTEN
  • Publication number: 20200191800
    Abstract: Provided are methods for determining whether a glioblastoma (GBM) tumor or GBM cancer cell will be sensitive to a treatment targeting the integrin avb3 (?v?3) pathway, comprising determining whether the GBM tumor or the GBM cancer cell expresses both avb3+ and Glut3+ along with a specific genetic signature associated with Glut3 addiction, where in alternative embodiments a cell is Glut3 addiction if the GBM tumor or the GBM cancer cell has markers consistent with the Classical or the Proneural molecular subtypes of GBM, or, expresses markers consistent with a Glut3-addicted molecular signature, e.g., as listed in FIG. 11 or FIG. 23. Also provided herein are methods of treating glioblastoma (GBM) tumors found to be sensitive to agents targeting or inhibiting the integrin avb3 (?v?3) pathway, wherein the sensitivity is determined by methods as provided herein.
    Type: Application
    Filed: June 14, 2018
    Publication date: June 18, 2020
    Inventors: David CHERESH, Sara Weis, Erika COSSET
  • Publication number: 20200109205
    Abstract: Provided are compositions and methods for treating or ameliorating a cancer by targeting cell surface-expressed ALPHA-V BETA-3 polypeptides in Cancer Stem Cells (CSCs) to kill the CSCs, to treat cancers caused or initiated by cancer or tumor 10 cells, or Cancer Stem Cells (CSCs), expressing ALPHA-V BETA-3 polypeptides on their cell surfaces. Provided are compositions and methods for targeting and killing ALPHA-V BETA-3-positive Cancer Stem Cells (CSCs) and treating drug resistant cancers. In alternative embodiments, compositions and methods as provided herein use an antibody that can specifically bind to human ALPHA-V BETA-3 that also comprises an Fc portion that can mediate antibody-dependent cell-mediated cytotoxicity (ADCC) killing of cancer cells by macrophages; for example, use a humanized antibody to ALPHA-V BETA-3 that has been modified to include an engineered Fc portion that specifically binds to human macrophages.
    Type: Application
    Filed: March 30, 2018
    Publication date: April 9, 2020
    Inventors: David CHERESH, Hiromi WETTERSTEN
  • Publication number: 20200061124
    Abstract: Provided are methods for making highly dedifferentiated and stem-like human cells from human umbilical vein endothelial cells (HUVECs) ectopically expressing integrin ?3. Also provided are methods for making ectoderm, mesoderm, and endoderm cells from HUVECs ectopically expressing integrin ?3. Also provided are methods for making neural cells, or cells having neuronal-like morphology, from HUVECs ectopically expressing integrin ?3. Provided are methods for making cardiomyocytes, or cells having cardiomyocyte-like morphology, from HUVECs ectopically expressing integrin ?3. Provided are methods for the production of pluripotent stem cells comprising expressing integrin ?3 in primary human endothelial cells. In alternative embodiments, provided are methods for inducing ?v?3 clustering, and to accelerate or facilitate angiogenesis, tissue remodeling or repair, or wound healing, for example, to accelerate healing after an infarction.
    Type: Application
    Filed: December 1, 2017
    Publication date: February 27, 2020
    Inventors: Joseph WAWRZYNIAK, David CHERESH
  • Publication number: 20180223376
    Abstract: In alternative embodiments, provided are products of manufacture, such as assays, chimeric nucleic acids and nucleic acid constructs, recombinant cells, and methods, comprising use of beta3-integrin (ITGB3) promoters operatively linked to a reporter, for drug screening, and in particular, screening for agents that inhibit cancer cell survival and metastasis. In alternative embodiments, compositions and methods as provided herein also can be used to identifying novel pathways that lead to acquired resistance, stemness, and anchorage independent growth; and characterizing distinct populations of cancer cells within a tumor microenvironment.
    Type: Application
    Filed: March 20, 2018
    Publication date: August 9, 2018
    Inventors: David CHERESH, Maricel GOZO, Mayra YEBRA, Laetitia SEGUIN
  • Publication number: 20180203014
    Abstract: Provided are compositions, including kits, and methods comprising use of a biomarker ?3 integrin, including the ?v?3 integrin, for detecting circulating tumor cells (CTCs), tumor stem cells, extracellular vesicles (EV), including exosomes and microvesicles, that are released by CTCs or cancer cells, as well as the tumor from which the CTCs or EVs derive, and to make a patient prognosis, and to assess tumor progression, and drug resistance (for example, resistance to tyrosine kinase inhibitors), e.g., for several cancers including: breast, colon, lung and pancreatic cancers. In alternative embodiments, a patient fluid sample, e.g., a blood, serum, urine, CSF or other sample, is taken and used to detect cancer stem cells, EVs- and/or CTCs-comprising ?3 integrin and/or a ?v?3 integrin. Provided are compositions, including kits, and methods and uses of the biomarker ?3 integrin for anti-cancer drug design.
    Type: Application
    Filed: April 20, 2016
    Publication date: July 19, 2018
    Inventors: David A. CHERESH, Laetitia SEGUIN, Yu FUJITA, Sara WEIS
  • Patent number: 9903855
    Abstract: In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing Growth Factor Inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a Growth Factor inhibitor on a cell, or, a method for re-sensitizing a cell to a Growth Factor Inhibitor, comprising for example, administration of a combination of a TBK1 inhibitor and an RTK inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: February 27, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David Cheresh, Laetitia Seguin, Sudarshan Anand, Jacqueline Lesperance
  • Publication number: 20180000821
    Abstract: In alternative embodiments, provided are compositions and methods for treating, enhancing the drug sensitivity of, and preventing the formation of cancer stems cells, including preventing or slowing the development or generation of a beta-3 (?3)-expressing, or integrin ?3 (ITG-B3)-expressing cancer or tumor cells. In alternative embodiments, provided are methods using histone acetyl transferase inhibitors and/or histone methyl transferase inhibitors to determine therapeutic values in cancer cells that induce an integrin ?3 (ITGB3) polypeptide expression. In alternative embodiments, provided are kits, blister packages, lidded blisters or a blister card or packet, clamshells, trays or shrink wraps, comprising at least one compound, composition or formulation used to practice a method as provided herein, and at least one Growth Factor Inhibitor.
    Type: Application
    Filed: December 18, 2015
    Publication date: January 4, 2018
    Inventors: David A. CHERESH, Maricel GOZO, Mayra YEBRA, Laetitia SEGUIN
  • Patent number: 9632074
    Abstract: In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing Growth Factor Inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a Growth Factor inhibitor on a cell, or, a method for re-sensitizing a cell to a Growth Factor Inhibitor, comprising for example, administration of a combination of a TBK1 inhibitor and an RTK inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: April 25, 2017
    Assignee: The Regents of the University of California
    Inventors: David Cheresh, Laetitia Seguin, Sudarshan Anand
  • Publication number: 20170022576
    Abstract: In alternative embodiments, provided are products of manufacture, such as assays, chimeric nucleic acids and nucleic acid constructs, recombinant cells, and methods, comprising use of beta3-integrin (ITGB3) promoters operatively linked to a reporter, for drug screening, and in particular, screening for agents that inhibit cancer cell survival and metastasis. In alternative embodiments, compositions and methods as provided herein also can be used to identifying novel pathways that lead to acquired resistance, stemness, and anchorage independent growth; and characterizing distinct populations of cancer cells within a tumor microenvironment.
    Type: Application
    Filed: March 18, 2016
    Publication date: January 26, 2017
    Inventors: David CHERESH, Maricel GOZO, Mayra YEBRA, Laetitia SEGUIN
  • Publication number: 20160237064
    Abstract: The present invention is directed to methods and compositions for suppressing lymphangiogenesis, angiogenesis and/or tumor growth. The methods comprise contacting the tumor with a compound that (i) stabilizes a protein kinase in the inactive state and (ii) is not an ATP competitive inhibitor of the protein kinase in the active state.
    Type: Application
    Filed: February 12, 2016
    Publication date: August 18, 2016
    Inventors: Eric A. MURPHY, David A. CHERESH, Lee Daniel ARNOLD
  • Publication number: 20160146783
    Abstract: In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing Growth Factor Inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a Growth Factor inhibitor on a cell, or, a method for re-sensitizing a cell to a Growth Factor Inhibitor, comprising for example, administration of a combination of a TBK1 inhibitor and an RTK inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell.
    Type: Application
    Filed: October 14, 2015
    Publication date: May 26, 2016
    Inventors: David CHERESH, Laetitia SEGUIN, Sudarshan ANAND
  • Patent number: 9260417
    Abstract: The present invention is directed to methods and compositions for suppressing lymphangiogenesis, angiogenesis and/or tumor growth. The methods comprise contacting the tumor with a compound that (i) stabilizes a protein kinase in the inactive state and (ii) is not an ATP competitive inhibitor of the protein kinase in the active state.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: February 16, 2016
    Assignee: AMITECH THERAPEUTIC SOLUTIONS, INC.
    Inventors: Eric A. Murphy, David A. Cheresh, Lee Daniel Arnold
  • Patent number: 9242000
    Abstract: In alternative embodiments, the invention provides compositions and methods comprising use of microRNAs and microRNA inhibitors to modulate blood vessel growth (angiogenesis), e.g., act as anti-angiogenic agents, and modulate cell and tumor microenvironment patterning, cancer cell and tumor growth and malignant disease (metastasis). In alternative embodiments, the invention provides compositions and methods that can sensitize blood vessels, e.g., tumor blood vessels, to radiation and agents and chemotherapies that cause DNA damage.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: January 26, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David Cheresh, Sudarshan Anand, Sunil Advani
  • Publication number: 20160015709
    Abstract: In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing Growth Factor Inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a Growth Factor inhibitor on a cell, or, a method for re-sensitizing a cell to a Growth Factor Inhibitor, comprising for example, administration of a combination of a TBK1 inhibitor and an RTK inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell.
    Type: Application
    Filed: July 7, 2014
    Publication date: January 21, 2016
    Inventors: David CHERESH, Laetitia SEGUIN, Sudarshan ANAND